Related Experiment Video
Updated: Aug 6, 2026

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
Published on: September 8, 2011
Neuromuscular effects and intubating conditions following mivacurium: a comparison with suxamethonium
V R Maddineni1, R K Mirakhur, E P McCoy
1Department of Anaesthetics, Queen's University of Belfast.
Abstract:
Mivacurium chloride has been assessed in respect of intubating conditions and neuromuscular effects. The influence of suxamethonium on the onset and duration of subsequently administered mivacurium was also studied. A dose of 0.15 mg.kg-1 of mivacurium was found to provide unacceptable intubating conditions at 2 min in 9/9 patients and further studies were conducted using 0.2 mg.kg-1. Intubating conditions with this dose were acceptable in 65% and 80% of patients at 2 min and 2.5 min respectively. In comparison, intubating conditions were acceptable in 100% of patients at 1 min following 1 mg.kg-1 of suxamethonium. The onset of block occurred in 96 s and 97 s after 0.15 mg.kg-1 and 0.2 mg.kg-1 respectively, and the durations of block in terms of recovery of the first twitch (T1) to 25% and 90% of control, and to recovery of train-of-four ratio to 0.7, were 16.1 and 17.9; 24.1 and 25.8; and 24.2 and 27.0 min respectively with the two doses. The time for the onset of complete block with suxamethonium 1.0 mg.kg-1 was 50 s and the times to 25% and 90% recovery were 9.8 min and 13.3 min. The differences between suxamethonium and both doses of mivacurium were significant (p < 0.05) but there were no significant differences between the two doses of mivacurium in any of the neuromuscular measurements. Prior administration of suxamethonium had no influence on the effects of mivacurium. Cutaneous flushing was observed in 30 out of 75 patients but this was associated with transient hypotension in only two patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
Mivacurium chloride at 0.2 mg.kg-1 provided acceptable intubating conditions in most patients, but suxamethonium offered faster results. Prior suxamethonium did not alter mivacurium
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Mivacurium chloride is a neuromuscular blocking agent.
- Suxamethonium is a commonly used neuromuscular blocking agent.
Purpose of the Study:
- To assess intubating conditions and neuromuscular effects of mivacurium chloride.
- To investigate the influence of suxamethonium on mivacurium's onset and duration.
Main Methods:
- Mivacurium chloride was administered at doses of 0.15 mg.kg-1 and 0.2 mg.kg-1.
- Intubating conditions and neuromuscular block parameters were evaluated.
- The effect of prior suxamethonium administration on mivacurium was studied.
Main Results:
- 0.2 mg.kg-1 mivacurium provided acceptable intubating conditions in 65-80% of patients.
- Suxamethonium (1 mg.kg-1) provided acceptable intubating conditions in 100% of patients within 1 minute.
- Mivacurium's onset was significantly slower than suxamethonium, with no significant difference between mivacurium doses. Prior suxamethonium did not affect mivacurium's neuromuscular effects.
- Cutaneous flushing occurred in 30% of patients, with transient hypotension in two.
Conclusions:
- Mivacurium chloride at 0.2 mg.kg-1 offers a viable alternative for neuromuscular blockade, though with a slower onset than suxamethonium.
- Suxamethonium provides superior intubating conditions compared to mivacurium.
- Mivacurium's neuromuscular effects are not influenced by prior suxamethonium administration.
Related Concept Videos
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Depolarizing Blockers: Pharmocokinetics
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Skeletal Muscle Relaxants: Therapeutic Uses

